10-Year Survival 68.5% After Thermal Ablation of Oligometastatic RCC

In 50 patients with oligometastatic renal cell carcinoma, percutaneous image-guided thermal ablation achieved 10-year overall survival of 68.5%, cancer-specific survival 75.5%, and local tumor progression-free survival 87.6%; adverse events occurred in 9.9% of procedures.

• Cohort included 50 patients with 100 lesions treated in 91 ablation procedures; mean follow-up 8.0 years.
• Primary and secondary technical success rates were 99% and 100%, respectively; 10-year local tumor progression-free survival was 87.6% with no significant difference by histology, size, disease location, or energy.
• Adverse events occurred in 9.9% (9/91) of procedures, all mild or moderate and mostly self-limited.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.